EVAR.F Stock Overview
Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Lombard Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.000001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | -100.00% |
| 5 Year Change | -99.98% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| EVAR.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 4.3% | 2.4% |
| 1Y | n/a | 16.9% | 25.0% |
Return vs Industry: Insufficient data to determine how EVAR.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how EVAR.F performed against the US Market.
Price Volatility
| EVAR.F volatility | |
|---|---|
| EVAR.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: EVAR.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine EVAR.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Kurt Lemvigh | www.lombardmedical.com |
Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally. The company’s principal product is Aorfix, which is an endovascular stent-graft for the treatment of abdominal aortic aneurysms (AAAs) with angulation at the neck of the aneurysm of up to 90 degrees. Its products also include Altura endovascular stent graft system for the treatment of standard AAA anatomies; Aorflex delivery system for accurate placement of Aorfix in the abdominal aorta; and IntelliFlex LP delivery system that enhances the precision and control of Aorfix deployment and placement.
Lombard Medical, Inc. Fundamentals Summary
| EVAR.F fundamental statistics | |
|---|---|
| Market cap | US$27.00 |
| Earnings (TTM) | -US$31.03m |
| Revenue (TTM) | US$12.17m |
0.0x
P/S Ratio0.0x
P/E RatioIs EVAR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVAR.F income statement (TTM) | |
|---|---|
| Revenue | US$12.17m |
| Cost of Revenue | US$11.03m |
| Gross Profit | US$1.14m |
| Other Expenses | US$32.18m |
| Earnings | -US$31.03m |
Last Reported Earnings
Dec 31, 2016
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did EVAR.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/25 19:17 |
| End of Day Share Price | 2023/11/28 00:00 |
| Earnings | 2016/12/31 |
| Annual Earnings | 2016/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lombard Medical, Inc. is covered by 5 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sean Lavin | BTIG |
| Lorenza Castellon | Equity Development Limited |
| Simon Conway | Evolution Securities |